UGT1A10 is involved in the metabolism of drugs like atorvastatin, axitinib, valproic acid, methotrexate, and irinotecan through glucuronidation, impacting their bioavailability, elimination, and therapeutic levels. This enzyme's activity variances can alter drug efficacy and side effect profiles, making the personalization of dosages based on genetic makeup imperative for optimizing therapeutic outcomes and minimizing adverse effects.